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Continuous chemotherapy in responsive metastatic breast cancer: a role
for tumour markers?
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Summary A biochemical response index comprising ESR, CEA and CA 15.3 was evaluated in 67 patients
with systemic breast cancer treated by chemotherapy; 55 were assessable by UICC criteria and the response
index (96% of all UICC assessable patients). Marker changes at 2 and 4 months showed a highly significant
correlation with the UICC assessed response at 3 and 6 months (P<0.001); sensitivity 100%, specificity 87%;
positive predictive value 85%; negative predictive value 100%.
This index was then used to select out truly responsive patients and to prospectively direct their chemo-
therapy. Twenty-six responding (biochemical/clinical) patients were randomised to discontinue cytotoxics after
6 months and move to maintenance hormones (n = 13) or continue chemotherapy whilst the biochemical
markers kept falling or remained within the normal range. Biochemical progression prompted a change of
chemotherapy. Continuous chemotherapy in biochemically defined responders was associated with a significant
lengthening of remission duration and an improved quality of life and survival. We are now using the index to
routinely direct chemotherapy and select out true responders for maintenance chemotherapy.
As yet there is no single ideal tumour marker for breast
cancer and no established role. Combinations of serum
markers, including carcinoembryonic antigen (CEA), have
been investigated in an attempt to increase the sensitivity of
detecting metastases (Franchimont et al., 1976; Coombes et
al., 1988; Cowen et al., 1978; Cove et al., 1979). Very few
studies have looked at combinations in measuring response
to therapy. On retrospective and prospective analyses we
have shown that changes in CEA, ESR and CA 15.3 individ-
ually correlate with therapeutic response in patients with
metastatic breast cancer treated by first-line hormones (Wil-
liams et al., 1990; Robertson et al., 1992). In a prospective
study, 93% of patients were assessable with a sensitivity for
response of 92% and specificity 82% (Robertson et al.,
1992). This present study examines the index in patients
receiving chemotherapy and describes our experience ofusing
objective biochemical assessment to direct individual patient
therapies.
Patients and methods
Sixty-seven consecutive patients with systemic breast cancer
who had failed to respond/relapsed on primary hormonal
therapies or proceeded straight to chemotherapy were stud-
ied. Patients were assessed prior to commencing chemo-
therapy and at 6-8 weekly intervals by clinical examination,
skeletal survey, routine haematology/biochemistry and serum
markers (CEA, ESR, CA 15.3). Other investigations e.g.,
bone and CT scans were performed if clinically indicated.
The median ages of the 55 assessable patients was 55 years
(range 26-75 years). Treatment regimens comprised (i)
mitozantrone 14 mg m2 3 weekly for four cycles (n = 21)
followed by 28 day cycles of CMF and (ii) 28 day cycles of
CMF (n = 34) at a standard dosage schedule. The major sites
of metastatic disease included bone (n = 24), pulmonary
(n = 8), bone and pulmonary (n = 7) and visceral (n = 16).
Patients unassessable for response by UICC (Hayward et
al., 1979) criteria (n = 2) or who died within 6 weeks (n = 8)
were excluded from the analysis. Two patients remained
biochemically unassessable throughout the study period. To
qualify for an objective response (complete/partial) or static
disease the minimum duration was considered 6 months
(British Breast Group, 1974). Comparisons were made
between assessments by UICC criteria with a minimum dura-
tion of remission or statis disease of 6 months and the
changes in the biochemical markers measured at 6-8 and
12-16 weeks. In analysing the correlation between bio-
chemical marker movement and UICC assessed response,
objective responders and static disease were combined into a
non-progressive disease group and compared with those
patients that showed disease progression.
Biochemical assessment ofresponse
The biochemical score was calculated in the same manner as
described for the first-line endocrine studies (Williams et al.,
1990; Robertson et al., 1992). Namely, any change in marker
whilst the patient is on therapy is related to the pretreatment
value. A cut-off for each marker of the mean + 2 s.d. of the
normal controls was calculated. Patients who never showed
an elevation of the marker above this level were regarded as
biochemically unassessable for that particular marker. Patients
with an initial pre-treatment value below the cut-off which
subsequently rose above the cut-off or patients with an initial
value above the cut-off which subsequently increased above
the inter-assay coefficient of variation (i.e., >10%) were
regarded as showing an increasing marker level (scored +2),
indicative of biochemical progression. Patients who started
with an initially high value which fell to below the cut-off or
patients with an initial value above the cut-off which subse-
quently decreased by more than the inter-assay coefficient of
variation for that marker (i.e., >10%) were regarded as
showing a decreasing marker level (scored - 2), indicating a
biochemical response; ESRs falling by >10% were scored
-1. Patients with levels which started and remained above
the cut-off but which moved by less than the inter-assay
coefficient of variation were regarded as being biochemically
stable and scored + 1. These changes and the scoring attach-
ed to them are summarised in Table I. Scores for the individ-
ual markers were then added together to produce an overall
biochemical index. Total scores >0 were considered as bio-
chemical progressors whilst an index score of <0 was con-
sidered a biochemical response.
Statistical analyses
Actuarial survival - response duration analysis was per-
formed using the statistical package SPSSX-21 (SPSS Inc.,
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1986) life table analysis which calculates Gehan's generalised
Wilcoxon rank test for censored data (Lee & Desu, 1972).
Response/remission duration and survival were calculated
from first treatment. Chi-squared analysis with Yates correc-
tion where appropriate was used to compared frequencies of
integers between two variables. Paired independent measure-
ments of continuous data were analysed using the Wilcoxon
signed ranks sum test. Unpaired data were examined using
the non-parametric Mann-Whitney U test.
Serum markers
ESR was measured within normal laboratory hours on the
day of venepuncture using the Westergren technique. Serum
markers were not measured immediately for practical pur-
poses. All samples were assayed in duplicate and blind of
clinical information on aliquots frozen and thawed once.
Ca 15.3 was measured using the commerically available two
site radio-immunoassay CIS ELSA kits (CIS UK, High
Wycombe). Despite the kit containing standards up to 250 U
ml-', linearity was only demonstrable between 30 and 140 U
ml-'. The inter-assay coefficients of variation (CV) was
9.2%. CEA was measured using an in-house Unilever ELISA
utilising a magnetically responsive solid phase, the mono-
clonal antibody 85A12 and a biotinylated detector polyclonal
antibody - alkaline phosphatase-streptavidin conjugate.
Intra- and inter-assay CVs were 6.2% and 8% respectively.
Prospective clinical study using markers to direct therapy
A small pilot prospective study was undertaken to examine
the biochemical index in directing patient therapy. Twenty-
six patients (19 from previous study group, seven additional
patients) who had achieved objective UICC and a tumour
marker assessed response following 6 months of first-line
cytotoxic therapy were randomised to:
(1) Discontinued cytotoxic therapies (n = 13) and change to
tamoxifen until clinical evidence of disease progression
(control group).
(2) Continue the same cytotoxic regimen (n = 13) until the
serum tumour markers rose by >10% of the trough
value or moved out of the normal range (marker
directed) at which point therapy would be changed.
All 26 patients were receiving 28 day cycles of a standard
CMF regimen at the time of randomisation. Patients ran-
domised to the tumour marker directed group were all made
fully aware of the experimental nature of the proposed pro-
tocol and each gave written informed consent; they were
allowed to discontinue at their own request or if the supervis-
ing clinician thought it was in their best interest. Dosage
schedules were guided by serial blood counts and continued
whilst the WBC count was >2,500 mm-3 and platelets
>100,000 mm-3. After receiving 12 months of cytotoxics the
patients were given the option of continuing with oral CMF:
cyclophosphamide 150-200mg (Mondays), methotrexate 25-
50 mg (Wednesdays) and 5-fluoruracil 250-500 mg (Fridays),
again dependent upon haematological indices. Five of the 13
patients in the control group received further cytotoxics upon
later disease progression. Tumour marker estimations were
performed at the time of study entry and repeated every 2
months. Three monthly UICC assessments were undertaken
in the controls; X-rays were only requested in the marker
directed group when clinically indicated. Disease progression
and survival were calculated from the time of first treatment.
Quality of life questionnaires in the form of a Rotterdam
Symptom Checklist - RSCL (De Haes et al., 1990) were
completed at study entry and every 3 months; the question-
naire assessed symptoms over the preceding 3 days. The
RSCL contains three subscales: physical symptomatology
due to disease and/or treatment (22 items); psychological
symptoms (eight items) and activities of daily living (eight
items). All items are rated on a four point scale (e.g. 'I feel
tense', not at all (0); a little (1); somewhat (2); very much
(3)). The psychological subscale yields a maximum score of
24.
The median age of the 13 patients under UICC/clinical
direction (controls) was 58 years (range 41-69) in com-
parison to the 53 years (range 40-64) of the tumour marker
directed (study) group. The principle sites of metastatic
disease are shown in Table II.
Results
UICC assessed response was compared with the biochemical
index score comprised of CEA, CA 15.3 and ESR. The
previously set cut-off values (see Table I) were used for all
three markers (ie. CEA 6 ngml-', CA 15.3 33 Uml-' and
ESR 20 mm h-1); marker changes from the baseline value of
> ± 10% were regarded as significant (Williams et al., 1990;
Robertson et al., 1992). Using the three markers in combina-
tion 55 of 57 UICC assessable patients with systemic breast
cancer were biochemically assessable (96%). A strong cor-
relation (P<0.00) was observed between the biochemical
score calculated at 6-8 weeks and the UICC assessment at
3-4 months; sensitivity 89%; specificity 96%; positive predic-
tive value 96%; negative predictive value 89% (Table III). A
Table I Scores for changes in marker concentrations
Upper limit Normal Decrease Stable Increase
ofnormal limits (>10%) (±<10%) (±>10%)
CEA 6 ngml- I 0 -2 +1 +2
CA 15.3 33 U ml[' 0 -2 + 1 +2
ESR 20mmh-' 0 -1 +1 +2
Individual markers scores are then added together to given the
biochemical index score.
TableII Principalsitesofmetastaticdiseaseintheprospectivestudyof
using markers to guide cytotoxic administration
Control group Study group
(6/12 chemotherapy) (Continuous chemotherapy)
Bone 5 4
Pulmonary 2 1
Bone and pulmonary - 3
Visceral 6 5
Table III CEA, ESR and CA 15.3 vs UICC response (>± 10%)
(i) Pre-treatment vs 6-9 weeks in 55 assessable patients
Biochemical Index Score
3-4/12 UICC response <0 >0
Response 21 0
Static 5 3
Progression 1 25
X2 = 37.03; 1 d.f.: P = 0.0000 (Combining response and static
disease).
Sensitivity = 89%; Specificity = 96%; PPV = 96%; NPV = 89%
(ii) Pre-treatment vs 12-16 weeks in 55 assessable patients
Biochemical Index Score
3-4/12 UICC assessment I0 >0
Response 20 1
Static 4 4
Progression 3 23
X2 = 25.074; 1 d.f.: P = 0.0000 (Combining response and static
disease).
Sensitivity = 83%; Specificity = 88%; PPV = 89%; NPV = 82%
(iii) Pre-treatment vs 12-16 weeks in 55 assessable patients.
Biochemical Index Score
3/12 UICC assessment (0 >0
Response 21 0
Static 2 0
Progression 4 28
XI = 37.569; 1 d.f.: P = 0.0000 (Combining response and static
disease).
Sensitivity = 100%; Specificity= 87%; PPV = 85%; NPV = 100%
PPV = +ve predictive value; NPV =-ve predictive value.CONTINUOUS CHEMOTHERAPY IN BREAST CANCER 183
comparison of the 3 month biochemical score against the 3
and 6 months UICC assessment produced a similar signifi-
cant correlation.
Of the 23 patients assessed as having non-progressive
disease after 6 months of therapy, 100% had biochemical
score <0 at 12-16 weeks. Twenty-two patients (95%) had
similar scores when the analysis was performed 6 weeks
earlier. In contrast, 28 and 23 (84-87%) patients UICC
assessed at 6 months as disease progressors had biochemical
index scores >0 (biochemical progression) at 2 and 3 months
respectively. Six of the eight patients assessed clinically
(UICC) as having static disease following four cycles of
cytotoxic therapy progressed during the following 3 months
despite continuation of what was thought to be a clinically
effective therapy; four of these patients were assessed bio-
chemically at 2months as disease progressors. These data
suggests that an erroneous 3-4 month classification of stable
disease can be avoided in some cases if the biochemical score
is taken into account and so allow for an earlier change of
cytotoxic regimens or simply palliation alone.
Prospective clinical study using markers to direct therapy
Side effects were at a minimum in both treatment groups.
Three patients in the control group had sufficient alopecia
(WHO grade 3) during the initial 6 month course of cyto-
toxic to require a wig; a fourth developed a similar degree of
alopecia in response to a course of doxorubicin upon subse-
quent relapse. Alopecia (WHO grade 3) was seen in two of
the 13 patients randomised to the tumour marker directed
group, this was despite maintenance cytotoxic therapy con-
tinuing for up to 26 months in some individuals. Four
patients receiving maintenance cytotoxics experienced a rapid
rejuvenation of initial hair loss (WHO grade 2-3) that had
been sustained through a previous course of mitozantrone.
Anticipatory vomiting complicated four cycles of main-
tenance cytotoxic therapy in one patient, nausea/vomiting
(WHO grades 1-2) were reported by a further two. All 26
patients were prescribed the anti-emetic metaclopramide
(10 mg 8 hourly) if required. Myelosuppression sufficient to
require both a re-scheduling ofplanned cytotoxic administra-
tions and dosage reduction occurred in three patients receiv-
ing maintenance chemotherapy, one of whom required a
transfusion for anaemia; a single control patient required a
blood transfusion prior to her fourth dose of mitozantrone.
None of the 13 patients randomised to receive maintenance
chemotherapy has requested to discontinue.
There were no differences in quality of life (QOL) total
scores between the two groups upon entry into the study
(Mann Whitney U statistic = 51; P = 0.48) or after the initial
6 month period of chemotherapy (Mann Whitney U statis-
tic = 38.5; P = 0.48). The 6 month period of initial chemo-
therapy which had produced both an objective clinical and
biochemical assessment of response in both sets of patients
was also associated with an improved quality of life (falling
threshold); the Wilcoxon matched-pair signed rank test statis-
tic was 9 (P = 0.030) for controls and 0.0 (P = 0.004) for the
study group. Whilst QOL total scores significantly increased
(worsening quality of life) in the control group over the 3
month period following completion of cytotoxic therapy
(Mann Whitney U statistic = 8.5; P = 0.04) before plateauing
between 9 and 15 months, further improvements (falling
scores) were recorded at 15 months in the group randomised
to receive maintenance chemotherapy under tumour marker
direction (Mann Whitney U statistic = 7.5; P = 0.05). All but
two patients in the tumour marker directed (study) group
recorded total scores within the normal range at 12 months;
this compared to only three controls. Total quality of life
scores with standard error bars are shown in Figure 1.
Despite the small number of patients entered into this
preliminary study, a statistically significant difference (P<
0.00) was observed in the period of clinical remission dura-
tion/disease control in favour ofthe marker guided/continuous
chemotherapy group (median 21 months) compared to the
patients randomised to discontinue cytotoxics (median 12
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Figure 1 Total quality of life scores for patients receiving either
a 6/12 course or continuous chemotherapy whilst tumour markers
continued to fall. (Mean and standard error bars).
months) after 6 months (Figure 2). The median time to
biochemical progression (17 months) for those who received
marker directed treatment was significantly lengthened (P=
0.05) over the time to clinical disease progression in the
control group who discontinued chemotherapy. The observed
advantages of a longer clinically apparent remission duration
and improved quality of life were carried through into im-
proved patient survival (P = 0.04) as calculated from the time
of first treatment; 27 months compared to 17 months (Figure
3).
Discussion
We have confirmed that the biochemical index derived for
patients receiving first-line endocrine therapy (Williams et al.,
1990; Robertson et al., 1992) is also applicable to patients
treated by chemotherapy. A highly significant correlation was
observed between the 3 and 6 month UICC response assess-
ments and changes in biochemical index (CEA, CA 15.3 and
ESR) calculated after 6-8 and 12-16 weeks of chemo-
therapy. The data also suggest that a 3 month classification
of stable disease is not a clinically useful categorisation as
most of these patients have an early relapse on continuation
of the same cytotoxic. Early relapse may be avoidable if the
assessment is made using the biochemical index and so allow
for an earlier change of therapy.
Changes in the three markers appears to reflect the dyna-
mics of a changing tumour mass in response to therapy in
contrast to the UICC criteria which reflect structural
changes. Potentially this would allow for the adoption of a
more rational approach in deciding when to change or con-
tinue systemic therapies in that they provide an objective
early measure of response or therapeutic failure. Marker
estimations can also be performed quickly in a cost effective
manner. One problem that has not been solved in measuring
mucin epitopes is shedding. Epitopes of the mucins may be
hidden and become available during chemotherapy. The
phenomenon of spiking after the onset of chemotherapy is
known in the case of CEA and probably also occurs with
CA 15.3. In general this only takes some weeks. The three
false negative biochemical scores >0 at 6-9 weeks were
associated with 6 weeks estimations in patients receiving
mitozantrone. Markers appear to have a potentially major
role in the selection of 'true' objective responders to chemo-
therapy. If these people can be successfully identified the
continued administration ofcytotoxic therapy, whilst tumour
marker levels continue to fall, appears to be advantageous.
Significant survival benefit is now well established for
adjuvant chemotherapy. In contrast it has proved much
harder to show that chemotherapy prolongs survival for
advanced disease. This dilemma lies at the root of controver-
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Figure 2 Duration of clinical response for control and study patients and biochemical progression in the marker directed group.
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Figure 3 Survival of control and continuous chemotherapy (marker directed) groups from first treatment.
sies about its role in metastatic cancer. In 1980, Powles et al.,
examined survival patterns in a group of patients, 50% of
which had received combination chemotherapy post-1974
and compared them to a similar group treated pre-1974 (a
period during which only 24% received combination chemo-
therapy). No significant difference was seen between the two
groups, indeed the earlier group had, overall, a longer survi-
val. The authors stated that their clinical observations
suggested that some aptients with life-threatening visceral
metastases did in fact have a survival benefit but that other
patients, notably those with more indolent disease, may
merely have suffered the toxicity and side effects of chemo-
therapy without any of the benefits. These observations have
been confirmed by others (Paterson et al., 1982; Patel et al.,
1986).
There are surprisingly few published data on the optimum
duration of chemotherapy. In a small trial (Smalley et al.,
1976) 24 patients who responded to five-drug combination
chemotherapy were randomised to stop after 24 weeks or to
continue indefinitely; no survival advantage was seen for
patients on maintenance treatment. A similar trial comparing
6 and 12 month maintenance chemotherapy was carried out
in 31 patients treated with CMF or MMM chemotherapy
(Smith, I.E., personal communication, 1990). Again no signi-
ficant difference was found in progression-free survival or
overall survival. This trial also demonstrated the difficulty in
maintaining long-term chemotherapy; of 15 patients random-
ised to receive continuous chemotherapy, only three managed
to complete 12 courses, with the rest stopping because of
progressive disease or cumulative haematological toxicity.
Identical findings were reported in an earlier study (Horto-
bagyi et al., 1981). The 100% reported in our small study
may relate to our adoption of a more gentle less stringent
regimen i.e., our use of oral CMF and occasionally 35 day
cycles for IV regimens and its administration to responsive
patients only.
In contrast to these findings, a large (308 patients) ran-
domised Australian study (Coates et al., 1987) compared
three courses of combination chemotherapy (cyclophospha-
mide, methotrexate, 5-flurouracil and prednisolone) resuming
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only when disease progressed with the same treatment given
continuously until relapse; the hope was that the intervals of
freedom from cytotoxic chemotherapy would contribute to
an improved quality of life. The tumour response rate (33%)
for intermittent therapy was significantly lower than the 44%
observed with continuous chemotherapy. Short duration
chemotherapy was also associated with a significantly shorter
time to disease progression and a trend towards a shorter
survival, with relative risk of mortality of 1.4 (95% con-
fidence interval 1.10-1.79; P = 0.0007). In addition, this trial
showed that short duration chemotherapy was associated
with poorer overall quality of life score as assessed by symp-
tom control, mood and general well-being. As expected, no
differences were seen between the two patient groups during
the first three cycles. It is important to note that the con-
tinuous policy yielded superior quality of life even in patients
whose best tumour response was stable disease as well as
those whose tumour responded. Further supportive evidence
is provided by a randomised Canadian trial (Tannock et al.,
1988) comparing two dose levels of CMF. As anticipated,
LASA scores showed a trend towards more nausea and
significantly greater hair loss for patients receiving high dose
treatment. No differences were detected for vomiting, mucos-
itis or diarrhoea. However, those patients receiving the higher
dose schedule showed a trend towards better symptom relief
and general well-being including pain, mobility housework,
anxiety and improved social life. This improvement cor-
related with patients on the higher dosage schedule achieving
better response rates (30% vs 11%) and significantly improv-
ed survival (16 months vs 13 months).
Overall it would seem that the beneficial effects of cyto-
toxic chemotherapy in controlling disease outweigh the nega-
tive effect of treatment related side-effects and result in an
improvement in quality of life as perceived by the patient.
These findings are in accord to those reported within this
paper. The described trial does not compare tumour marker
directed chemotherapy against clinical directed chemotherapy
but rather continuous vs intermittent chemotherapy. The
value of the tumour markers was in selecting the study
population i.e., only patients who had shown an objective
biochemical response following 6 months administration of
cytotoxics. If we can truly identify chemosensitive - re-
sponding patients and continue prescribing maintenance
chemotherapy whilst the response continues then further
improvements in quality of life, disease stabilisation and
survival may be anticipated; tumour markers offer the
attending clinician this ability. Fears of excess financial costs
from biochemical monitoring were not substantiated in a
subsequent study (unpublished findings).
If these findings are substantiated, the nihilistic approach
frequently adopted by many clinicians to the treatment of
this disease wil need reconsideration. A logical continuation
of this study is to examine continuous chemotherapy (marker
directed) in biochemical responders and compare against
continuous chemotherapy whilst tolerable in UICC respond-
ers (clinical directions); such a trial is currently underway.
A.R. Dixon is funded by Unilever Research, Colworth Laboratory,
Sharnbrook, Bedford.
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